Higher lipoprotein(a) levels are associated with an increased progression of coronary plaque burden. Dr. Mik Rinne discusses a study on the efficacy of the CDK2 inhibitor BLU-222 in patients with HR+/HER2- breast cancer. Dr. Mithu Maheswaranathan on a study that shows metformin is a promising complementary therapy for SLE. A factor secreted by tumor cells is responsible for the resistance of melanoma to treatment. Long-term and short-term risk should be assessed when considering when to start hypertension medication. Dr. Anne Marie Morse discusses the link between cancer and sleep and circadian science. Among patients with T2DM, the risk of dementia and Alzheimer disease is lower in those treated with metformin. COVID-19 infection accelerates disease progression in children and adolescents with presymptomatic type 1 diabetes. A study aimed to assess the long-term survival outcomes and disease patterns of male breast cancer patients. Monitoring heart rate and physical activity using a wearable device has clinical value. Dr. Anne Marie Morse discusses the challenges of treating children and adolescents with narcolepsy. Older women who undergo complex heart surgery are more likely than men to receive care at low-quality hospitals. Researchers developed a tool to predict nervous system side effects experienced by breast cancer patients using taxanes. Dr. Anne Marie Morse details how having a sleep disorder can impact personal and professional relationships. Researchers developed an at-home questionnaire test that quickly identifies people at high risk of heart attack. New research may explain recurrent Crohn disease in children, and it may open the door for novel treatments. A year of treatment with the antibody-drug conjugate trastuzumab emtansine effectively prevents HER2-positive BC ... Adam Elsesser, of Penumbra, talks about a novel system for removing venous thrombus and treating pulmonary embolism. Dr. Anne Marie Morse, who was in attendance at SLEEP 2024, recapped the most notable research from the event. Both rare and common genetic variation is associated with an increased risk of atrial fibrillation.